BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17457042)

  • 1. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.
    Kapoor GS; Christie A; O'Rourke DM
    Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
    Yu X; Guo ZS; Marcu MG; Neckers L; Nguyen DM; Chen GA; Schrump DS
    J Natl Cancer Inst; 2002 Apr; 94(7):504-13. PubMed ID: 11929951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
    Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
    Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.
    Wang W; Cheng B; Miao L; Mei Y; Wu M
    Cell Death Dis; 2013 Apr; 4(4):e574. PubMed ID: 23559009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
    Zhan Y; Counelis GJ; O'Rourke DM
    Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma.
    Babu D; Chintal R; Panigrahi M; Phanithi PB
    Cell Oncol (Dordr); 2022 Dec; 45(6):1451-1465. PubMed ID: 36284039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.
    Lai ZY; Tsai KY; Chang SJ; Chuang YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
    Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G
    Zhang YX; Li XF; Yuan GQ; Hu H; Song XY; Li JY; Miao XK; Zhou TX; Yang WL; Zhang XW; Mou LY; Wang R
    J Biol Chem; 2017 May; 292(21):8933-8947. PubMed ID: 28341744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of signal regulatory protein alpha1 inhibitory receptors by epidermal growth factor receptor signaling.
    Kapoor GS; Kapitonov D; O'Rourke DM
    Cancer Res; 2004 Sep; 64(18):6444-52. PubMed ID: 15374953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
    Dong P; Xu Z; Jia N; Li D; Feng Y
    Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation.
    Fiano V; Ghimenti C; Imarisio S; Silengo L; Schiffer D
    Anticancer Res; 2004; 24(5A):2643-7. PubMed ID: 15517868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.